Could 'guy-necologists' improve men's health?

Some experts say sperm can be a proxy for the health of the person who produced it, giving insight into far more than fertility.   ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

February 21, 2026 Check out STAT+

Sponsored By

Maria Fabrizo for STAT Should semen analysis become the Pap smear for men? Some men's health experts say yes Despite scientific skepticism of semen analysis as a biomarker for overall health, entrepreneurs see a new way to get men to visit a doctor. By Annalisa Merelli Camille MacMillin/STAT STAT+ | In a financial pinch, major health insurers are turning to AI for help Health insurers promise artificial intelligence will result in frictionless care, but providers have concerns about denials and lack of transparency. By Casey Ross Adobe Biohackers and wellness influencers are pushing nicotine as part of their 'stacks' From tech offices to fitness influencers, nicotine is being sold as a focus and productivity boost. Experts say addiction and legal risks are being downplayed. By Sarah Todd STAT+ | As oncologists ponder how to integrate AI-powered cancer tools, products are hitting the market New digital pathology AI tools, including from Valar Labs, claim to predict chemotherapy response in pancreatic cancer. Doctors see both promise and risk. By Angus Chen Opinion: I took part in a 2012 psilocybin trial. What I'm seeing now horrifies me For-profit companies are underplaying a key component of psychedelic therapy, the human guides that manage the setting and help interpret the experience. By Erica Rex Opinion: My biggest GLP-1 ethical problem: patients who don't want to stop I used to struggle with GLP-1 shortages. Now I'm facing the opposite problems: excess medication for some patients. By Jody Dushay STAT+ | The FDA's Moderna pirouette is one more sign of chaos at the agency While the FDA may get past the latest crisis, over a review of a flu vaccine, the volatility at the agency may be here to stay. By Matthew Herper STAT+ | 5 key people to watch at HHS after Trump's shake-up Trump administration makes personnel changes in advance of midterm elections. STAT looks at five power players at the top of the HHS org chart. By Chelsea Cirruzzo

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Weekend Reads? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser